04/17/2026
🚨 BIG FDA UPDATE 🚨
The FDA reported yesterday (April 15, 2026) that it will imminently remove some of the bulk drug substances for 12 peptides. Originally nominated for Category 2 (Bulk Substances that Raise Significant Safety Concerns), the withdrawal of these nominations would indicate that the FDA is reconsidering the validity of respective safety concerns. Removal from Category 2 also lessens restrictions on US compounding pharmacies ability to produce these peptides. The FDA announcement also suggests that its July 2026 meeting will evaluate each substance on its scientific merits using full clinical, pharmacological, and safety evidence.
So, what does this mean for our patients and the future of wellness?
✨ A shift toward science-driven decision making
✨ Increased opportunity for regulated, provider-guided peptide use
✨ Reduced reliance on unregulated sources
✨ A step forward in bringing innovative therapies into a safer, more structured clinical setting
At 1513, our priority has always been patient safety, education, and results. We’re watching these developments closely and are committed to integrating advancements the RIGHT way—backed by data, compliance, and clinical expertise.
The landscape is changing—and it’s opening the door for better, safer access to therapies our patients are asking for 👏
We will keep you informed as progress develops 👩🏼💻
🩺 💉
